Zhang Qing, Xing Zhijun, Bai Lu, Li Xiao, Xu Fan
Departments of Oncology, Affiliated Hospital of Chengde Medical University, Chengde, China.
Division of General Thoracic Surgery, Department of Surgery, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto, 390-8621, Japan.
Sci Rep. 2025 Jul 24;15(1):26868. doi: 10.1038/s41598-025-12557-8.
Higher expression of Complement C1q-like protein 4 (C1ql4) in breast cancer may be associated with increased tumor malignancy. As a protein involved in immune responses and inflammation, C1ql4 is expressed across all molecular subtypes of breast cancer. We conducted a retrospective analysis and follow-up study involving 111 patients who underwent breast cancer resection at the Department of Breast Surgery, Affiliated Hospital of Chengde Medical College, to investigate the relationship between C1ql4 expression and overall survival, as well as to evaluate the prognostic value of C1ql4 both independently and in combination with conventional clinicopathologic parameters. Chi-square analysis revealed a significant positive difference between C1ql4 protein expression and TNM staging, as well as molecular subtypes. Moreover, patients with high C1ql4 expression demonstrated significantly poorer prognoses. In conclusion, our findings suggest that C1ql4 expression may serve as a potential biomarker for elevated breast cancer malignancy.
补体C1q样蛋白4（C1ql4）在乳腺癌中的高表达可能与肿瘤恶性程度增加有关。作为一种参与免疫反应和炎症的蛋白质，C1ql4在乳腺癌的所有分子亚型中均有表达。我们进行了一项回顾性分析和随访研究，纳入了111例在承德医学院附属医院乳腺外科接受乳腺癌切除术的患者，以研究C1ql4表达与总生存期之间的关系，并独立以及联合传统临床病理参数评估C1ql4的预后价值。卡方分析显示，C1ql4蛋白表达与TNM分期以及分子亚型之间存在显著的正相关差异。此外，C1ql4高表达的患者预后明显较差。总之，我们的研究结果表明，C1ql4表达可能是乳腺癌恶性程度升高的潜在生物标志物。
